Johnson & Johnson $JNJ Stock: 1834 Investment Advisors Co. Reduces Holdings

Key Points

• 1834 Investment Advisors reduced its Johnson & Johnson stake by 13.9% in the third quarter, selling 5,046 shares and retaining 31,305 shares valued at $8.29 million. Institutional investors and hedge funds still own 69.55% of JNJ.
• Johnson & Johnson reported third-quarter revenue of $25.4 billion and adjusted EPS of $2.59, beating estimates, while raising its 2026 operational sales outlook to approximately $100.7 billion. Pharmaceutical momentum and pipeline investments supported results, but MedTech sales weakness remains a key concern.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and average price target of $274.87. JNJ also affirmed its $1.34 quarterly dividend, equivalent to a 2.1% annualized yield, although the stock’s premium valuation and recent insider selling warrant caution.

1834 Investment Advisors Co. cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,305 shares of the company's stock after selling 5,046 shares during the quarter. 1834 Investment Advisors Co.'s holdings in Johnson & Johnson were worth $8,288,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. USA Financial Formulas purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at $609,000. New England Research & Management Inc. raised its stake in Johnson & Johnson by 0.5% in the 3rd quarter. New England Research & Management Inc. now owns 29,662 shares of the company's stock valued at $7,853,000 after acquiring an additional 135 shares during the period. Berman McAleer LLC raised its stake in Johnson & Johnson by 0.5% in the 3rd quarter. Berman McAleer LLC now owns 30,001 shares of the company's stock valued at $7,942,000 after acquiring an additional 137 shares during the period. Guardian Asset Advisors LLC lifted its holdings in Johnson & Johnson by 2.1% during the third quarter. Guardian Asset Advisors LLC now owns 5,572 shares of the company's stock valued at $1,474,000 after purchasing an additional 112 shares during the last quarter. Finally, RKL Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.3% during the third quarter. RKL Wealth Management LLC now owns 27,711 shares of the company's stock valued at $7,336,000 after purchasing an additional 343 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson?
• Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target.
• Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying
• Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss
• Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations.

Analyst Ratings Changes

A number of brokerages recently commented on JNJ. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research note on Friday. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a research note on Wednesday. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Finally, Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $274.87.

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 0.0%

Shares of JNJ stock opened at $255.54 on Monday. The company has a market capitalization of $615.82 billion, a PE ratio of 38.72, a price-to-earnings-growth ratio of 2.53 and a beta of 0.21. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The business's fifty day moving average is $265.66 and its 200 day moving average is $249.66. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same period in the previous year, the business earned $2.80 earnings per share. The firm's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.